secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regulus Therapeutics Inc. (—)
CIK:        0001505512
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001104659-25-062408
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novartis closes tender offer for Regulus; holders get $7.00 cash plus $7.00 CVR
-------------------------------------------------------------------------------

- Tender offer expired June 24 with 74.49% shares tendered; merger completed June 25.
- Shareholders receive $7.00 cash per share plus a CVR that could pay $7.00 if U.S. regulatory approval for ADPKD achieved.
- Regulus stock will be delisted from Nasdaq effective June 25.
- All prior directors and officers removed; replaced by Novartis appointees John McKenna and Eduard Marti.
- Charter and bylaws amended and restated; company becomes Novartis subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505512/000110465925062408/0001104659-25-062408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505512/000110465925062408/tm2518614d30_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-062408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer